Napabucasin: Additional Phase Ib/II data

Data from a cohort of 27 patients with non-small cell lung cancer (NSCLC) in the open-label, North American Phase Ib/II BBI608-201 trial showed that twice-daily oral napabucasin, starting at a dose of 240 mg, plus paclitaxel led to a disease control rate (DCR) of 56%, with tumor regression occurring in 26% of patients and an objective partial response (PR) occurring in 11% of patients. Median progression-free survival (PFS) was 16 weeks and median overall survival (OS) was 34 weeks.

In a cohort of 56 patients with platinum-resistant epithelial ovarian, fallopian or peritoneal cancer, twice-daily 240-480 mg napabucasin plus paclitaxel led to a DCR of 48%, overall response rate (ORR) of 18%, median PFS of 15 weeks and median OS of 38 weeks. Prior to evaluation, 2 patients withdrew due to neuropathy, 6 withdrew for other adverse events, 5 for deterioration, 2 for noncompliance and 1 for unrelated myocardial infarction (MI). ...